TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01678716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHC + BCC
Description: This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
Study: NCT02796131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Study: NCT01678716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHC + BCC
Description: This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powders
Description: In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powders
Description: In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
Study: NCT03333330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque 320 and SonoVue
Description: Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS
Study: NCT04529421

Intervention type: BEHAVIORAL
Intervention: Online instruction
Description: For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.

Intervention type: BEHAVIORAL
Intervention: Online instruction
Description: For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
Study: NCT02796131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Study: NCT04529421

Intervention type: BEHAVIORAL
Intervention: Online instruction
Description: For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.

Intervention type: BEHAVIORAL
Intervention: Online instruction
Description: For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.

Intervention type: BEHAVIORAL
Intervention: Online instruction
Description: For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.

Intervention type: BEHAVIORAL
Intervention: Online instruction
Description: For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
Study: NCT02796131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04529421

Intervention type: BEHAVIORAL
Intervention: In-person instruction
Description: For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).

Intervention type: BEHAVIORAL
Intervention: In-person instruction
Description: For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
Study: NCT02796131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04327440

Intervention type: BIOLOGICAL
Intervention: RTS,S/AS01 malaria vaccine
Description: Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.

Intervention type: OTHER
Intervention: PBO bed nets
Description: PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting

Intervention type: OTHER
Intervention: PBO bed nets
Description: PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
Study: NCT02901613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Study: NCT00653965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT02621034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: K-file hand instrumentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc
Description: reciprocating rotary instrument

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One shape
Description: full rotation protocol
Study: NCT02860065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC-201
Description: solifenacin and donepezil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: measure activity of cerebral acetylcholinesterase
Study: NCT02091141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Study: NCT01421342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching: Bupropion-SR
Description: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmenting: Antidepressant + Bupropion-SR
Description: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmenting: Antidepressant + Aripiprazole
Description: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
Study: NCT02150967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398 (infigratinib)
Description: Capsule for oral use
Study: NCT04498572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: dry needling for Gluteus Medius muscle in combination with exercises

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham dry needling
Description: sham dry needling for Gluteus Medius muscle in combination with exercises
Study: NCT03039933

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fear of Hypoglycemia
Description: Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
Study: NCT01904721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 1
Description: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 1
Description: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 1
Description: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 2
Description: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Study: NCT03039933

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Treatment As Usual
Study: NCT02190747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00641524

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phlebotomy
Description: Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
Study: NCT02076659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F8IL10
Description: Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Study: NCT02800486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Mannitol

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated re-irradiation
Study: NCT02937532

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GHE + TOBT training
Description: All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
Study: NCT01904721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 2
Description: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Solution 2
Description: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Vehicle
Description: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Vehicle
Description: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimatoprost Vehicle
Description: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
Study: NCT03332121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B001
Description: 4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
Study: NCT00532844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride and Vitamin C
Description: Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
Study: NCT01382771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular corticosteroid injection
Description: Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular saline injection
Description: Intra-articular injection of 0.5 cc normal saline in each joint
Study: NCT04096417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05908838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Banxia Xiexin Decoction
Description: The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: combination chemotherapy with Placebo granules
Description: combination chemotherapy with Placebo granules
Study: NCT03734822

Intervention type: OTHER
Group type: OTHER
Intervention: End tidal CO2 (EtCO2)
Description: End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous CO2 (TCO2)
Description: Continuous and noninvasive real-time monitoring of transcutaneous CO2.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Capillary CO2 (CapCO2)
Description: Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Arterial blood gas (ABG)
Description: Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
Study: NCT03822078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection
Study: NCT02519257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAD
Description: Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VHD
Description: Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
Study: NCT04201093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Participants will be randomized to receive tavapadon 5 mg QD or 15 mg QD tablet once daily orally for 27 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Participants will be randomized to receive tavapadon 5 mg QD or 15 mg QD tablet once daily orally for 27 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Study: NCT04530916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: 22 g/day wild blueberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 22 g/day placebo powder
Study: NCT03733470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil study group
Description: One dose of 20 mg Sildenafil will be given one hour before CT imaging.
Study: NCT02076659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Study: NCT01638026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIPTORELIN ACETATE, hCG
Description: In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.